MA33466B1 - Composition d'insuline à longue duree d'action - Google Patents

Composition d'insuline à longue duree d'action

Info

Publication number
MA33466B1
MA33466B1 MA34581A MA34581A MA33466B1 MA 33466 B1 MA33466 B1 MA 33466B1 MA 34581 A MA34581 A MA 34581A MA 34581 A MA34581 A MA 34581A MA 33466 B1 MA33466 B1 MA 33466B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
insulin compound
action
long term
insulin composition
Prior art date
Application number
MA34581A
Other languages
Arabic (ar)
English (en)
Inventor
Kennett Sprogøe
Felix Cleemann
Ulrich Hersel
Silvia Kaden-Vagt
Torben Lessmann
Harald Rau
Thomas Wegge
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA33466B1 publication Critical patent/MA33466B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPOSÉ D'INSULINE À UNE CONCENTRATION SUFFISANTE POUR MAINTENIR UN NIVEAU THÉRAPEUTIQUEMENT EFFICACE DU COMPOSÉ D'INSULINE DANS LE PLASMA SANGUIN PENDANT AU MOINS 3 JOURS, LADITE COMPOSITION PHARMACEUTIQUE ÉTANT CARACTÉRISÉE PAR UN PROFIL PHARMACOCINÉTIQUE IN VIVO NE PRÉSENTANT PRATIQUEMENT AUCUN PIC DUDIT COMPOSÉ D'INSULINE. LA PRÉSENTE INVENTION CONCERNE, EN OUTRE, L'UTILISATION D'UN COMPOSÉ D'INSULINE POUR LA PRÉPARATION DE LADITE COMPOSITION PHARMACEUTIQUE, AINSI QU'UN NÉCESSAIRE CONTENANT LADITE COMPOSITION PHARMACEUTIQUE.
MA34581A 2009-07-31 2010-07-30 Composition d'insuline à longue duree d'action MA33466B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09167017 2009-07-31
EP09179337 2009-12-15
EP09179827 2009-12-18
PCT/EP2010/061160 WO2011012719A1 (fr) 2009-07-31 2010-07-30 Composition d'insuline à action prolongée

Publications (1)

Publication Number Publication Date
MA33466B1 true MA33466B1 (fr) 2012-07-03

Family

ID=43033453

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34581A MA33466B1 (fr) 2009-07-31 2010-07-30 Composition d'insuline à longue duree d'action

Country Status (29)

Country Link
US (1) US9265723B2 (fr)
EP (1) EP2459171B1 (fr)
JP (1) JP5732053B2 (fr)
KR (1) KR101759499B1 (fr)
CN (1) CN102625695B (fr)
AU (1) AU2010277560B2 (fr)
BR (1) BR112012001988A2 (fr)
CA (1) CA2769540C (fr)
CL (1) CL2012000469A1 (fr)
CO (1) CO6491085A2 (fr)
CR (1) CR20120019A (fr)
DK (1) DK2459171T3 (fr)
EC (1) ECSP12011631A (fr)
ES (1) ES2636741T3 (fr)
GT (1) GT201200020A (fr)
IL (1) IL217613A (fr)
MA (1) MA33466B1 (fr)
MX (1) MX2012001141A (fr)
NI (1) NI201200013A (fr)
NZ (1) NZ597964A (fr)
PE (1) PE20121170A1 (fr)
PL (1) PL2459171T3 (fr)
PT (1) PT2459171T (fr)
RU (1) RU2556340C2 (fr)
SG (1) SG178195A1 (fr)
TN (1) TN2012000010A1 (fr)
UA (1) UA108475C2 (fr)
WO (1) WO2011012719A1 (fr)
ZA (1) ZA201200224B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019000248B8 (pt) * 2004-03-23 2021-07-27 Complex Biosystems Gmbh reagente de ligador de pró-fármaco de cascata polimérico
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2012216648C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP2014534265A (ja) * 2011-11-28 2014-12-18 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド インスリンアミノ酸配列を含む治療薬
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CA2907848A1 (fr) 2013-04-03 2014-10-09 Sanofi Traitement du diabete sucre par des formulations d'insuline a longue action
JP2017503017A (ja) * 2013-12-18 2017-01-26 ウィンドギャップ メディカル， インコーポレイテッド 薬物混合および送達システムならびに方法
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
WO2015104314A1 (fr) * 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisées d'analogues de l'insuline et/ou de dérivés de l'insuline
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
CN105899190B (zh) * 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
WO2016100949A2 (fr) 2014-12-18 2016-06-23 Windgap Medical, Inc. Procédé et compositions permettant de dissoudre ou de solubiliser des agents thérapeutiques
CN105796508A (zh) * 2014-12-30 2016-07-27 江苏万邦生化医药股份有限公司 甘精胰岛素缓释微球、甘精胰岛素微球注射剂及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MY196308A (en) 2016-03-01 2023-03-24 Ascendis Pharma Bone Diseases As PTH Prodrugs
US20190224122A1 (en) 2016-09-23 2019-07-25 Delpor, Inc. Stable compositions for incretin mimetic compounds
DK3518961T3 (da) * 2016-09-29 2023-04-24 Ascendis Pharma Bone Diseases As PTH-forbindelser med lave forhold mellem top og bund
HRP20231079T1 (hr) 2016-09-29 2023-12-22 Ascendis Pharma Bone Diseases A/S Režim za doziranje pth spoja s kontroliranim oslobađanjem
US10869851B1 (en) * 2017-03-13 2020-12-22 The United States Government As Represented By The Secretary Of The Army Targeting NUR77 for mitigating perinatal neuroinflammation
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
EP3844169A4 (fr) 2019-08-16 2021-12-15 Applied Molecular Transport Inc. Compositions, formulations et production et purification d'interleukines
MX2022009523A (es) 2020-02-18 2022-09-09 Novo Nordisk As Formulaciones farmaceuticas.

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
PT627911E (pt) 1992-02-28 2001-04-30 Univ Texas Hidrogeis biodegradaveis fotopolimerizaveis como materiais de contacto de tecidos e veiculos de libertacao controlada
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
ES2297902T5 (es) 1997-11-14 2013-07-09 Amylin Pharmaceuticals, Inc. Compuestos novedosos agonistas de exendina
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU6419899A (en) 1998-10-09 2000-05-01 Regents Of The University Of Michigan, The Hydrogels and water soluble polymeric carriers for drug delivery
US7744912B1 (en) 1999-02-01 2010-06-29 Eidgenossische Technische Hochschule Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
EP2100901A1 (fr) 1999-05-17 2009-09-16 ConjuChem Biotechnologies Inc. Insuline modifiée et ses conjugués
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6602952B1 (en) 1999-06-11 2003-08-05 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
CA2398788A1 (fr) 2000-01-28 2001-08-02 Infimed Therapeutics, Inc. Polymeres contenant des proteines a liberation lente
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (fr) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Prodrogues activables à séparateurs allongés et multiples
JP4340067B2 (ja) 2001-04-23 2009-10-07 ウィスコンシン アルムニ リサーチ ファウンデイション 二機能性改変ハイドロゲル
YU98503A (sh) 2001-05-21 2006-05-25 Nektar Therapeutics Pulmonarno ordiniranje hemijski modifikovanog insulina
EP1306127B2 (fr) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Procédé pour la préparation de particules purifiées
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003084926A2 (fr) 2002-04-04 2003-10-16 Enzon, Inc. Derives acyles polymeriques d'indoles
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
CA2487720A1 (fr) 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Agent therapeutique contenant des nanoarticles polymeriques
WO2003104426A2 (fr) 2002-06-10 2003-12-18 Merck & Co., Inc. Molecule d'acide nucleique isolee codant une proteine de type moteur associee a un centromere, et ses utilisations
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
CA2521784C (fr) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
NZ541374A (en) 2003-05-23 2008-09-26 Nektar Therapeutics Al Corp PEG derivatives having an amidocarbonate linkage
EP1525890A1 (fr) 2003-10-02 2005-04-27 Complex Biosystems GmbH Complexes protéine-protéophore
BR122019000248B8 (pt) 2004-03-23 2021-07-27 Complex Biosystems Gmbh reagente de ligador de pró-fármaco de cascata polimérico
EP1586334A1 (fr) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugés avec PEG
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (fr) 2004-10-01 2006-04-13 Kyushu University, National University Corporation Cellule novatrice de production de stéroïde
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
CA2593165A1 (fr) 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Conjugues analgesiques
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007053946A1 (fr) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Procede de traitement du diabete et/ou de l'obesite en reduisant les effets secondaires nauseeux au moyen d'un peptide insulinotrope conjugue a de l'albumine
US8070810B2 (en) 2006-01-12 2011-12-06 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
EP1840152B1 (fr) 2006-03-31 2009-07-08 Sony Deutschland Gmbh Procédé de production d'un gel polymèrique réticulé
CA2653200A1 (fr) 2006-05-25 2007-12-06 The General Hospital Corporation Agents anti-reticulation et procedes permettant de bloquer la reticulation de preparations d'hydrogel injectables
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
GB0619175D0 (en) 2006-09-29 2006-11-08 Univ Nottingham Polymer
EP2099845B1 (fr) 2006-11-27 2020-12-23 Actamax Surgical Materials LLC Reactifs a extremites ramifiees et adhesifs tissulaires en hydrogel polymere associes
EP2121057A4 (fr) 2007-02-06 2012-10-10 Incept Llc Polymérisation avec précipitation de protéines pour élution dans une solution physiologique
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (fr) 2007-03-28 2008-10-02 Novo Nordisk A/S Composés peptidiques à pégylation biodégradable transitoire
JP2010523243A (ja) 2007-04-13 2010-07-15 クロス・バイオサージェリー・アクチェンゲゼルシャフト 高分子組織シーラント
EP2514412A1 (fr) * 2007-04-30 2012-10-24 Novo Nordisk A/S Solutions et compositions d'insuline fortement concentrée
AU2008258548B2 (en) * 2007-06-08 2014-07-10 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
JP5688969B2 (ja) * 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0906643A2 (pt) 2008-02-01 2019-09-10 Ascendis Pharma As profármaco compreendendo um conjugado fármaco-ligante
CA2711455C (fr) 2008-02-13 2016-06-07 Hyperbranch Medical Technology, Inc. Hydrogels a base de polyalkyleneimines reticulees a taux de degradation ajustable
EP2756756B1 (fr) 2008-04-28 2016-01-06 Zogenix, Inc. Compositions inédites destinées au traitement de la migraine
ES2875426T3 (es) 2008-04-29 2021-11-10 Ascendis Pharma Endocrinology Div A/S Compuestos de hormona de crecimiento humana recombinante pegilada
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
PL2459220T3 (pl) 2009-07-31 2021-03-08 Ascendis Pharma A/S Biodegradowalne nierozpuszczalne w wodzie hydrożele na bazie poli(glikolu etylenowego)
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
KR101756493B1 (ko) 2009-10-29 2017-07-10 아센디스 파마 에이에스 생분해성 하이드로겔의 살균
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine

Also Published As

Publication number Publication date
IL217613A (en) 2016-08-31
KR20120089261A (ko) 2012-08-09
US9265723B2 (en) 2016-02-23
WO2011012719A1 (fr) 2011-02-03
GT201200020A (es) 2014-09-10
KR101759499B1 (ko) 2017-07-19
US20120183616A1 (en) 2012-07-19
CA2769540C (fr) 2017-08-15
ZA201200224B (en) 2012-09-26
UA108475C2 (uk) 2015-05-12
PL2459171T3 (pl) 2017-11-30
SG178195A1 (en) 2012-03-29
CL2012000469A1 (es) 2012-10-19
RU2012107487A (ru) 2013-09-10
BR112012001988A2 (pt) 2017-05-09
CR20120019A (es) 2012-03-02
CA2769540A1 (fr) 2011-02-03
AU2010277560A1 (en) 2012-02-23
CN102625695A (zh) 2012-08-01
JP2013500952A (ja) 2013-01-10
NI201200013A (es) 2012-05-29
PT2459171T (pt) 2017-08-16
EP2459171B1 (fr) 2017-06-21
ECSP12011631A (es) 2012-02-29
CN102625695B (zh) 2015-05-27
AU2010277560B2 (en) 2014-12-11
JP5732053B2 (ja) 2015-06-10
DK2459171T3 (en) 2017-09-25
EP2459171A1 (fr) 2012-06-06
RU2556340C2 (ru) 2015-07-10
TN2012000010A1 (en) 2013-09-19
NZ597964A (en) 2014-04-30
MX2012001141A (es) 2012-03-29
ES2636741T3 (es) 2017-10-09
PE20121170A1 (es) 2012-09-10
CO6491085A2 (es) 2012-07-31

Similar Documents

Publication Publication Date Title
MA33466B1 (fr) Composition d'insuline à longue duree d'action
MA37740A1 (fr) Seringue
MA34748B1 (fr) Extraction d'eau de l'air
MA32703B1 (fr) Combinaison d'une insuline et d'un agoniste de glp 1
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
MA34457B1 (fr) Combinaison d'un composé glyt1 avec des agents antipsychotiques
MA33735B1 (fr) Composition pharmaceutique comprenant un agoniste du glp-1 et de la methionine
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
EA200970274A1 (ru) Способы введения гипогликемических средств с длительным действием
FR2929271B1 (fr) Procede pour la preparation du 1,2,3,3,3-pentafluoropropene- 1
MA32903B1 (fr) Inhibiteurs de proteine-kinases
DE502006006107D1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MA40308A1 (fr) Pyridine-2- amides utiles comme agonistes de cb2
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA38238A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
EA201270216A1 (ru) Фармацевтический состав
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
MA31776B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
MA42166B1 (fr) Seringue
NO20064783L (no) Opplosningstabeletter med licarbazepin
MA39110B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39109A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39108A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie sévère
MA43667B1 (fr) Nouveaux dérivés de pyrrolidine
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе